Ceftazidime-avibactam: Difference between revisions
From IDWiki
(→) |
No edit summary |
||
| Line 28: | Line 28: | ||
==Dosing== |
==Dosing== |
||
| − | *Ceftazidime-avibactam 2.5 g (2 g / 0.5 g) IV q8h, infused over |
+ | *Ceftazidime-avibactam 2.5 g (2 g / 0.5 g) IV q8h, infused over 3 hours |
| + | **Consider adjunctive [[aztreonam]] 2 g IV q8h infused concurrently over 3 hours for metallo-β-lactamase-producing carbapenem-resistant [[Enterobacterales]] or [[Stenotrophomonas maltophilia]] |
||
===Pediatric Dosing=== |
===Pediatric Dosing=== |
||
Latest revision as of 15:05, 24 November 2021
Background
- Brand name Avycaz
Mechanism of Action
- Ceftazidime is a third-generation cephalosporin
- Avibactam
- Inhibitis class A, C, and some class D beta-lactamases, includign OXA-48
- No activity against class B
- Reduces MIC to ceftazidime in most Enterobacterales including Pseudomonas
- Does not induce AmpC expression
- Slowly-reversible inhibitor that gets recycled
Spectrum of Activity
- GNBs
- Active against carbapenem-resistant Enterobaceriaceaea, including KPCs and AmpC beta-lactamases
- Restores activity with ceftazidime in Pseudomonas and other GNBs
- Poor activity against Acinetobacter and Stenotrophomonas
Pharmacokinetics and Pharmacodynamics
- Short half-life 2.7 hours
- Low protein binding
- Primarily renally cleared
Dosing
- Ceftazidime-avibactam 2.5 g (2 g / 0.5 g) IV q8h, infused over 3 hours
- Consider adjunctive aztreonam 2 g IV q8h infused concurrently over 3 hours for metallo-β-lactamase-producing carbapenem-resistant Enterobacterales or Stenotrophomonas maltophilia
Pediatric Dosing
- 3 months to <6 months: ceftazidime 40 mg/kg plus avibactam 10 mg/kg IV q8h, infused over 2 hours
- 6 months to <18 years: ceftazidime 50 mg/kg plus avibactam 12.5 mg/kg IV q8h, infused over 2 hours
